Celrixafor 24mg Injection

About

Celrixafor 24mg Injection is a hematopoietic stem cell mobilizer, specifically a CXCR4 chemokine receptor antagonist. It works by blocking the binding of stromal cell-derived factor-1 alpha (SDF-1α) to its receptor, CXCR4, on hematopoietic stem cells. This blockade disrupts the normal retention of stem cells within the bone marrow microenvironment, leading to their rapid release into the peripheral bloodstream. This mobilization is crucial for autologous stem cell transplantation, where a patient's own stem cells are collected, stored, and later reinfused after high-dose chemotherapy.

Celrixafor is typically used in combination with granulocyte-colony stimulating factor (G-CSF) to enhance the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and multiple myeloma. Its administration significantly increases the yield of CD34+ cells, improving the chances of successful stem cell collection and subsequent engraftment. The drug is administered subcutaneously and is generally well-tolerated, providing a vital option for patients who are poor mobilizers with G-CSF alone.

Uses

• Mobilization of hematopoietic stem cells in non-Hodgkin lymphoma
• Mobilization of hematopoietic stem cells in multiple myeloma
• Used for autologous stem cell transplantation
• Enhances stem cell collection when G-CSF alone is insufficient

Directions For Use

Celrixafor 24mg Injection is administered subcutaneously by a healthcare professional. It is typically given 6-11 hours before apheresis, following G-CSF treatment.

Benefits

• Significantly increases peripheral blood CD34+ cell count
• Improves the success rate of autologous stem cell collection
• Reduces the number of apheresis sessions required
• Provides an option for poor mobilizers with G-CSF alone
• Facilitates earlier and more robust engraftment post-transplant
• Enhances overall outcomes for stem cell transplantation

Side Effects

• Injection site reactions (pain, redness, swelling)
• Diarrhea
• Nausea and vomiting
• Fatigue
• Headache
• Dizziness
• Abdominal pain
• Flatulence
• Peripheral edema
• Arthralgia (joint pain)
• Insomnia
• Risk of splenic rupture (rare)

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but general caution is advised during medical procedures.
• Pregnancy - Celrixafor is not recommended during pregnancy due to potential fetal harm. Use effective contraception.
• Breastfeeding - It is unknown if Celrixafor is excreted in human milk; breastfeeding is generally not advised during treatment.
• Liver - No specific dose adjustment is required for hepatic impairment, but caution is advised in severe cases.
• Kidney - Dose adjustment is necessary for patients with moderate to severe renal impairment (CrCl < 50 mL/min).
• Lung - No specific lung-related safety concerns, but monitor for any unusual respiratory symptoms during treatment.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.